Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 3, 2005 Rich Duprey	Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA.
The Motley Fool August 22, 2005 Rich Duprey	Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies.
The Motley Fool May 24, 2005 Charly Travers	Genentech Eyes a New Market Will Lucentis be the next addition to the biotech giant's growing drug portfolio? Investors, take note.
The Motley Fool November 19, 2011 Luke Timmerman	Regeneron Wins FDA Approval for Macular-Degeneration Drug The company can begin selling Eylea, which treats the leading cause of blindness in the elderly.
The Motley Fool May 31, 2005 Karl Thiel	Is Eyetech Better Than It Looks? If you're a born contrarian with a little spare mad money lying around, this biotech could be worth buying at these levels.
Managed Care March 2005 Thomas Morrow	Aptamers: Slowing Progression of AMD A single strand of nucleic acid may hold the key to treating the leading cause of severe vision loss and blindness resulting from age-related macular degeneration.
The Motley Fool May 25, 2005 Tom Taulli	Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note.
Chemistry World May 9, 2011 Andrew Turley	New data reignites eye drug debate Interim results from a much anticipated comparative study of two drugs support what many ophthalmologists already believe: that ranibizumab and bevacizumab are equally good for the treatment of neovascular age related macular degeneration.
Bio-IT World December 15, 2004 Zachary Zimmerman	Silence Is Golden Life Science Insights believes that RNAi therapeutics will dramatically affect the pharmaceutical and healthcare industries, becoming the next major class of therapeutics, joining small molecules, proteins, and monoclonal antibodies.
The Motley Fool November 23, 2010 Brian Orelli	Less of a Poke in the Eye Regeneron Pharmaceuticals was up nearly 20% yesterday after the drugmaker announced the results for two phase 3 trials testing VEGF Trap-Eye in wet AMD patients.
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
The Motley Fool April 19, 2004 Charly Travers	4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry.
Chemistry World January 13, 2011 Andrew Turley	UK tilts towards appraisal of Avastin as eye drug The UK is moving closer to opening up the National Health Service to cancer drug Avastin (bevacizumab) for the treatment of eye conditions, such as age-related macular degeneration.
The Motley Fool July 12, 2010 Ryan McBride	Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009.
The Motley Fool April 27, 2011 Brian Orelli	Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
The Motley Fool October 2, 2007 Brian Orelli	Regeneron Sees Positive Phase 2 Data Regeneron Pharmaceuticals and partner Bayer HealthCare see a bright future for their age-related macular degeneration treatment after announcing positive phase 2 data.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
The Motley Fool July 30, 2010 Brian Orelli	3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.
Bio-IT World December 15, 2004 Nancy Weil	Running Interference The revolution in RNA interference has galvanized basic research. Now, some biopharmas are pushing the technology from the laboratory to the clinic.
The Motley Fool May 19, 2010 Brian Orelli	The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd.
The Motley Fool January 5, 2005 Rich Duprey	Sharks Don't Go Blind Shark liver oil shows promise in treatment of age-related macular degeneration. Genaera Corp. though leading this interesting investigation, is not profitable, racking up some significant losses over the years.
Chemistry World September 24, 2014 Phillip Broadwith	Review says cheaper drug is safe for eye disease Researchers have added weight to the argument that health services should use the cancer drug Avastin (bevacizumab) to treat age-related wet macular degeneration, instead of the more expensive Lucentis (ranibizumab).
Chemistry World May 21, 2014 Phillip Broadwith	Novartis enhances its focus with eyecare deal Swiss pharma major Novartis is continuing its quest to excel in a few specialist fields by licensing rights to US firm Ophthotech's lead candidate, Fovista, for wet age-related macular degeneration.
The Motley Fool September 8, 2010 Brian Orelli	You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.
Chemistry World July 2010 Hayley Birch	Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade.
BusinessWeek May 27, 2010 Pettypiece & Gibson	Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer."
The Motley Fool March 31, 2008 Brian Lawler	A Good Mix for QLT QLT takes one step closer toward a winning combination for those who suffer from macular degeneration.
Managed Care January 2004 Thomas Morrow	Choking Off a Tumor's Blood Supply Angiogenesis blockade is a 30-year-old concept, but it will soon make the leap from lab bench to pharmacy shelf.
The Motley Fool April 25, 2011 Luke Timmerman	Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it?
The Motley Fool March 16, 2011 Brian Orelli	Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial.
Managed Care August 2006 Thomas Morrow	New Injectable Medication Effective Against Wet AMD Age-related macular degeneration is the most common cause of blindness in people over age 55. This market will expand rapidly. Managed care should remain informed and start to manage this area.
The Motley Fool April 29, 2005 Tim Hanson	Genentech's Promising Future Cancer drug Avastin is finding new uses. How will outside forces affect its potential? Investors take note.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool July 5, 2006 Brian Lawler	Stay Away From QLT Competitive pressure on its top drug makes this company one investors should avoid.
The Motley Fool October 26, 2004 Charly Travers	Biotech's 5-Baggers: Part 2 Several hot drugs are generating smoking returns. If the goal for an investor is to aim for one of these five-baggers, then one option is to invest before the company passes through the inflection point.
The Motley Fool February 28, 2011 Brian D. Pacampara	Next-Generation Drug Technologies Battle It Out Alnylam and Sangamo BioSciences have different ways to manipulate proteins to fight disease.
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool March 31, 2011 Brian Orelli	Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?
The Motley Fool May 17, 2010 Luke Timmerman	Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool November 22, 2006 Brian Lawler	How to Market a Drug Too Well Cephalon's promotion of its pain drug Actiq might have crossed the line.
BusinessWeek January 21, 2010 John Carey	Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes.
The Motley Fool April 26, 2011 Luke Timmerman	FDA Says Vertex Drug a Wee Bit More Effective Than Advertised; Stock Climbs Good news for Vertex?
Pharmaceutical Executive July 30, 2007	Tomorrow's Drugs A look at the seven top therapies and technologies vying to deliver the next generation of drugs.
BusinessWeek May 24, 2004 Arlene Weintraub	Regenerative Medicine's Slow Start Scientists think proteins that spur the body to heal could make powerful drugs, but harnessing that potential has been tough
Chemistry World April 2, 2015 Emma Stoye	Novartis accused of 'derailing' trials for cheap eye disease drug The British Medical Journal has accused pharmaceutical giant Novartis of deliberately hindering research into the use of anticancer drug Avastin (bevacizumab) to treat age-related wet macular degeneration.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
Pharmaceutical Executive July 1, 2011 Dickmeyer & Rosenbeck	From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition?